Navigation Links
Delcath Announces Agreement With University Medical Center Schleswig-Holstein for Use of Its Hepatic CHEMOSAT Delivery System
Date:2/16/2012

to, uncertainties relating to: the future use and adoption of the CHEMOSAT system by the University Medical Center Schleswig-Holstein, future initial launch and training agreements with other cancer centers in Europe, CE Marking for the Generation Two system and the timing of our commercial launch in Europe, the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology
2. Delcath Receives Regulatory Approval to Commercialize Hepatic CHEMOSAT® Delivery System in Australia
3. Delcaths Ireland Operations Achieves ISO 13485 Certification
4. Delcath Announces Agreement With the Frankfurt University Hospital for Launch of Hepatic CHEMOSAT Delivery System in Germany
5. Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board
6. Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union
7. Delcath to Present at the Lazard Healthcare Conference on November 15
8. Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments
9. Delcath Systems to Report Third Quarter Progress and Conduct Conference Call
10. FDA Schedules Delcath Pre-New Drug Application Meeting Date
11. Delcath Announces Completion of Regulatory Notification Process in New Zealand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... of the "Infectious Disease Diagnostics Market by Product, ... report to their offering. , The ... CAGR of 7.9% to reach $18,156.2 million by 2019 ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... Diagnostics Market by Allergen Source, Product & by End User ... The global allergy diagnostics market is valued ... at a CAGR of 12.67%, to reach $2,230.72 million by ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "X-Ray Detectors Market by Detector Type, Applications & by FPD ... their offering. , The X-ray detectors market ... technological advancements since its inception, such as a shift from ...
Breaking Medicine Technology:Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3Global X-Ray Detectors (Flat Panel, Computed Radiography, CCD, Line-Scan) Market - Forecast to 2019 2Global X-Ray Detectors (Flat Panel, Computed Radiography, CCD, Line-Scan) Market - Forecast to 2019 3
... , , ... KERX ) today announced results of the Open Label ... of elevated serum phosphorous levels, or hyperphosphatemia, in patients with ... in Taiwan, enrolled 29 of the 37 Taiwanese patients that ...
... , , , ... today announced results from a Phase II trial of regorafenib (BAY 73-4506), ... in a 31 percent partial response rate and 50 percent stabilization rate ... in an oral session at the joint 15th Congress of the European ...
Cached Medicine Technology:Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 2Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 3Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 4Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... 22, 2015 Compare-autoinsurance.org has released a new blog ... an auto insurance policy . , Some types of ... should check the newly released blog post to see if their ... dangerously damaged vehicles are some of the cars that cannot be ...
(Date:1/22/2015)... USA (PRWEB) January 22, 2015 State ... statewide data management system with support from GEOSYSTEMS, a ... The new solution will leverage Hexagon Geospatial’s ERDAS ... vector data as well as point clouds and documents. ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... DaVita,s Efforts in Corporate Social Responsibility and Support ... Calif., May 22 DaVita Inc. (NYSE: ... care services for those diagnosed with chronic kidney ... and marketing departments received eight Hermes Creative Awards, ...
... breast cancer had additional malignant tumors found only by ... Medical Center. , A total of 199 patients ... found additional, unsuspected cancers in the ipsilateral breast (the ... 16% of patients; we found cancers in the contralateral ...
... issued the,following press release: , ... flurry of panic about,the H1N1 (swine influenza). School ... even suggested closing the border with Mexico,where approximately three ... every day. The panic certainly was fueled by ...
... CyberKnife Centers Are Meeting Increasing Demand for ... TechnologiesSUNNYVALE, Calif., May 22 Accuray Incorporated ... leader in the field of radiosurgery, announced ... patient throughput using their recently installed, next ...
... Effort Addressing the Leading Cause of Maternal Mortality to ... Every year, more than half a million of the ... crisis that has seen little to no improvement over ... by Pathfinder International capitalized on groundbreaking new technologies in ...
... Reach $500 Million by 2014PRINCETON, N.J., May 22 ... federal funds next year and more than $500 million ... rules proposed to take effect in October, according to ... Economics department examined the impact of three provisions under ...
Cached Medicine News:Health News:DaVita Wins Eight Hermes Creative Awards Recognizing Excellence in Communications and Marketing 2Health News:DaVita Wins Eight Hermes Creative Awards Recognizing Excellence in Communications and Marketing 3Health News:H1N1: What You Should Know 2Health News:H1N1: What You Should Know 3Health News:Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife 2Health News:Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife 3Health News:Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife 4Health News:New Initiative Poised To Reduce Maternal Mortality Rates By More Than 25 Percent 2Health News:N.J. Hospitals Face $97 Million in Medicare Cuts 2Health News:N.J. Hospitals Face $97 Million in Medicare Cuts 3
BD Vacutainer® Fluoride Tubes - Plastic...
Inquire...
Inquire...
... The inner wall of the serum ... particles, these particles activate the coagulation process. ... gel in the base of the tube; ... barrier between the serum and the blood ...
Medicine Products: